Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio is a biopharmaceutical company with a promising pipeline of oncology product candidates. The company generates revenue from out-licensing agreements and has recently entered into an exclusive collaboration agreement with Eisai to expand the global footprint of its lead program, IBTROZI. Risks to the attainment of the company's price target include potential delays in trial enrollment and competition from emerging products, which could lead to downward adjustments in timing and discount rates. However, we remain positive on the company's outlook, reiterating an OUTPERFORM rating and a price target of $11 based on a sum-of-parts valuation for their lead programs.

Nuvation Bio is advancing potentially differentiated therapeutic candidates in oncology, most notably taletrectinib for the treatment of ROS1+ non-small cell lung cancer. With initial data expected in 2027 for an exploratory cohort in grade 3 oligodendroglioma and topline data expected in 2029 for the registrational G203 study in high-grade IDH1-mutant glioma, Nuvation Bio is positioning itself for potential accelerated approval and significant commercial opportunities. While current revenues are primarily generated from out-licensing agreements, the company's upcoming earnings report and survey findings suggest strong potential for Ibtrozi's continued growth and eventual revenue stacking as patients remain on therapy for extended durations.